AstraZeneca’s Imfinzi and Imjudo immunotherapy combinations have been approved in the European Union for the treatment of advanced liver and lung cancers, the company announced. The approvals authorize Imfinzi in combination with Imjudo for the 1st-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma, or HCC, and Imfinzi in combination with Imjudo and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer, or NSCLC.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
- AstraZeneca, Merck present final results from Phase III PROpel trial
- Merck, AstraZeneca present final results from Phase 3 PROpel trial
- Compugen: Rilvegostomig expected to progress into Phase 3 this year
- Sophia expands deal with AstraZeneca to include MM approaches to oncology